Key result
Intensive LDL-C reduction improves secondary stroke prevention and may curb recurrent vascular events in neurorehabilitation.
Why the study?
The transition between acute ischemic stroke care and long-term outpatient management is a vulnerable period during which guideline-directed lipid-lowering therapy is frequently delayed, undertitrated, or discontinued. Neurorehabilitation may provide an important opportunity to address this gap and facilitate optimized lipid management.
Does integrating structured intensive lipid management into neurorehabilitation improve secondary stroke prevention and reduce recurrent vascular events in patients with ischemic stroke?
Does integrating structured intensive lipid management into neurorehabilitation improve secondary stroke prevention and reduce recurrent vascular events in patients with ischemic stroke?
Integrating structured lipid management into post-stroke neurorehabilitation offers a practical approach to bridge care gaps, optimize intensive LDL-C lowering, and reduce recurrent vascular events.
Answers are grounded in this paper and cite their sources.
Should not yet change neurorehabilitation practice; hypothesis-generating for structured lipid programs in secondary stroke prevention.
Background and PurposeIschemic stroke remains a major cause of death, disability, and recurrent vascular events worldwide. Although lipid-lowering therapy is central to secondary prevention, the transition between acute stroke care and long-term outpatient management remains a vulnerable period during which guideline-directed treatment is frequently delayed, undertitrated, or discontinued. Neurorehabilitation may provide an important opportunity to address this gap. This narrative review summarizes evidence supporting intensive low-density lipoprotein cholesterol (LDL-C) reduction after ischemic stroke and examines how the neurorehabilitation setting may facilitate optimized lipid management.MethodsA literature search was performed in PubMed/MEDLINE, Embase, and the Cochrane Library through March 2026, combining terms across three domains: (1) ischemic stroke and secondary prevention, (2) lipid-lowering therapy, and (3) neurorehabilitation and functional recovery. Included study types encompassed randomized controlled trials, systematic reviews with meta-analyses, clinical practice guidelines, observational cohort and preclinical studies addressing statin pleiotropic effects. Priority was given to landmark randomized trials, major society guidelines, and studies with direct relevance to recurrent stroke prevention, hemorrhagic risk stratification, and rehabilitation-based care delivery.ResultsEvidence from SPARCL, Treat Stroke to Target, FOURIER, and Ez PAVE shows that intensive LDL-C reduction improves secondary stroke prevention. Statins may also affect neuroinflammation, endothelial function, blood-brain barrier integrity, and neuroplasticity, with differences in hemorrhagic stroke risk and safety profiles compared with PCSK9 inhibitors.ConclusionAlthough direct rehabilitation-based randomized trials are lacking, integrating supervised medication titration, adherence monitoring, neuroimaging-guided risk stratification, and patient-centered secondary prevention strategies into neurorehabilitation may represent a practical approach for strengthening secondary stroke prevention and reducing recurrent vascular events.
No takes yet. Share an insight, caveat, or question.
Fezeu et al. (2026) conducted a review in Ischemic stroke. Intensive low-density lipoprotein cholesterol (LDL-C) reduction and neurorehabilitation-based lipid management was evaluated on Secondary stroke prevention and recurrent vascular events. Intensive LDL-C reduction improves secondary stroke prevention, and integrating structured lipid management into neurorehabilitation may help reduce recurrent vascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: